Investors & News

Latest News

Oct 19,2020
Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting
Sep 23,2020
Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting
Sep 10,2020
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September
All News

Stock Quote (MITO)

Share

Why invest?

Our Company

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.

Our Programs

We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.

Our Pipeline

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Latest Reports

August 07, 2020
Form 424B5 : Prospectus filed pursuant to Rule 424(b)(5)
HTML
August 07, 2020
Form 6-K : Report of Foreign Issuer
HTML
Reports

Latest Presentations

September 08, 2020
Investor Presentation September 2020
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
Presentations

Events

September 23, 2020
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 1:40 pm ET
Webcast
September 15, 2020
Cantor Fitzgerald's Virtual Global Healthcare Conference 2020 8:40 am ET
Webcast
Financial Calendar
Media Relations

Amelia Stetler, 617-762-2562
media@stealthbt.com

Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com